About Us

Developing products that are first-in-class with unique mechanism of action and are different from those of existing therapies

Pharmazz, Inc.

Pharmazz, Inc. is an innovative biopharmaceutical company with an approved product, promising drug pipeline and a seasoned management team. It is a Delaware Corporation based in Willowbrook, Illinois, USA focused on discovering, acquiring, developing, and commercializing therapeutics that target critical care medicine. Pharmazz India Private Limited a majority owned subsidiary of Pharmazz, Inc. obtained marketing authorization of Lyfaquin® (INN: Centhaquine) in India.

Pharmazz has licensed exclusive worldwide rights to several molecules indicated for critically ill patients from Midwestern University, Downers Grove, USA. The company has a strong patent position and robust pipeline in different stages of clinical development.


The company is developing three novel first-in-class drug products across multiple critical care indications. Its lead product, Centhaquine, is for Hypovolemic Shock where a new therapeutic is greatly needed. Pharmazz’s second compound, Sovateltide, is for cerebral ischemic stroke, Alzheimer’s disease, and other neurodegenerative diseases. A third compound is being developed for treatment of diabetic ketoacidosis and to eliminate opioid tolerance.


Explore Our Great History!!

Robust innovative pipeline to bring novel drug products for hospital-based therapies

The company accomplished centhaquine development from bench to bedside in ten years
Download Brochure

Media gallery